Intensity-modulated radiotherapy reduces acute and delayed G2+GI toxicities versus 3D-CRT in high-risk prostate cancer
Post hoc analysis shows IMRT reduces radiation side effects for high-risk prostate cancer
This post hoc analysis of a Phase III randomized controlled trial evaluated intensity-modulated radiotherapy (IMRT) versus three-dimensional…
A post hoc analysis of a Phase III trial found that intensity-modulated radiotherapy reduced radiation side effects compared to older techni…
Time to biochemical progression predicts second events in high-risk prostate cancer
Longer time to progression predicts better outcomes in prostate cancer
This phase 3 RCT of 413 men with high-risk localized prostate cancer found that a longer time from randomization to biochemical progression …
Men with high-risk prostate cancer who had a longer time before their cancer worsened were less likely to have further progression or spread…
Liquid biopsy shows high sequencing success in high-risk localized prostate cancer feasibility study
Blood Tests Replace Biopsies for Prostate Cancer
A phase 2 neoadjuvant trial in 22 patients with high-risk localized prostate cancer found liquid-based genomic profiling achieved 100% seque…
A simple blood draw now replaces painful prostate biopsies, capturing the same genetic details doctors need to pick the best treatment.
Research across Cancer
Related studies from across the Cancer family.
CAR T-cell therapies targeting specific antigens show potential for treating pediatric CNS tumors
New CAR T-cell therapies show promise for pediatric brain tumors
This narrative review synthesizes 18 studies, including preclinical and early-phase clinical trials, regarding CAR T-cell therapy for pediat…
CAR T-cell therapy is showing potential to shrink tumors and extend life in children with aggressive brain cancers like DIPG.
Targeted cytokine delivery platforms in canine oncology provide data for human immuno-oncology dose selection
Cytokine Therapies Show Potential for Treating Canine Cancers
This mini review synthesizes evidence on targeted cytokine delivery platforms, such as IL-12 and IFN-beta, in dogs with various spontaneous …
New research explores how targeted cytokine delivery systems can treat various cancers in dogs and provide data for future human cancer trea…
Immunohistochemical profiling helps differentiate synchronous primary breast invasive carcinoma from metastatic ovarian carcinoma
One woman diagnosed with two different types of cancer simultaneously
This case report and literature review describes a patient with concurrent primary breast cancer and metastatic high-grade serous ovarian ca…
A rare case reveals how one patient can have both breast and ovarian cancer at once, highlighting a complex diagnostic challenge.
Intracranial immunotherapy delivery does not improve survival for pediatric high-grade glioma compared to systemic administration
Intracranial Delivery Shows Higher Neurotoxicity Risk in Pediatric Brain Tumors
This meta-analysis of 22 studies evaluated intracranial versus systemic immunotherapy delivery in pediatric patients with high-grade and dif…
New analysis shows that while delivery methods do not change survival for pediatric brain tumors, some routes carry a higher risk of severe …
Hypofractionated and dose-boosted radiotherapy improves metastasis-free survival in clinically localised prostate cancer
Dose-boosting radiotherapy may improve survival for high-risk prostate cancer patients
This systematic review and meta-analysis evaluated hypofractionated and dose-boosted radiotherapy fractionation schedules versus standard ra…
Combining external beam radiotherapy with brachytherapy or a focal boost significantly improved metastasis-free survival in patients with cl…
Darolutamide plus ADT and docetaxel reduces death risk 37% in metastatic hormone-sensitive prostate cancer
New drug treatment lowers death risk for advanced prostate cancer patients by thirty seven percent
This phase 3 randomized controlled trial enrolled 472 European patients with metastatic hormone-sensitive prostate cancer. Darolutamide 600 …
A large study found that adding darolutamide to standard care helped European patients live longer and delayed cancer growth. Serious side e…
Follicular T cell subsets and tertiary lymphoid structures may guide immunotherapy in ovarian cancer
New immune targets offer hope for ovarian cancer patients
This narrative review synthesizes evidence on follicular T cell subsets, tertiary lymphoid structures, and other immune features in ovarian …
A review highlights new immune system features that could help doctors predict treatment success and find better ways to fight ovarian cance…
Case report details multimodal treatment for aggressive thyroid carcinoma
First new treatment combination in six months stabilizes advanced thyroid cancer
A 61-year-old man with papillary thyroid carcinoma achieved disease stabilization after thyroidectomy, radiotherapy, and targeted therapy. T…
A 61-year-old man with advanced thyroid cancer saw his disease stop growing after a specific mix of treatments within six months of his diag…
Case report of YL205 antibody-drug conjugate in platinum-resistant ovarian carcinoma
First patient achieves complete response with new ovarian cancer drug YL205
This is a single-patient case report of a 40-year-old woman with platinum-resistant, BRCA-wildtype high-grade serous ovarian carcinoma treat…
A single patient with advanced ovarian cancer achieved a complete response after 24 weeks of treatment with YL205, a new antibody-drug conju…
Systematic review and meta-analysis shows darolutamide combination therapy improves survival in advanced prostate cancer
Darolutamide plus ADT improves survival in advanced prostate cancer patients
This systematic review and meta-analysis of randomized controlled trials evaluated darolutamide combination therapy versus placebo plus ADT …
A large analysis of trials shows darolutamide combined with standard treatment extends life and delays cancer spread in advanced prostate ca…
Review of a case report on epithelioid clear cell mesothelioma in a 76-year-old male with 24 months follow-up
A 76-year-old man with rare cancer stayed cancer-free for two years
This publication is a review of a single case report involving a 76-year-old male with epithelioid clear cell mesothelioma. The patient had …
A 76-year-old man with a rare form of cancer had no signs of the disease returning after two years, offering hope for others facing this dif…
Enzalutamide plus ADT improves 5-year survival in metastatic hormone-sensitive prostate cancer
Prostate Cancer Drug Helps Men Live Years Longer, New Data Shows
This post hoc analysis of a phase 3 randomized controlled trial in 1150 patients with metastatic hormone-sensitive prostate cancer found tha…
Men with advanced prostate cancer who took enzalutamide lived years longer than those on standard treatment alone, according to five-year da…